Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) EPS (Weighted Average and Diluted) (2023 - 2025)

Goldenwell Biotech's EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$0.0 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 65.38% year-over-year to -$0.0; the TTM value through Sep 2025 reached -$0.0, up 65.38%, while the annual FY2024 figure was -$0.0, 12.05% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.0 in Q3 2025 per GWLL's latest filing, down from -$0.0 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.0 in Q4 2024 to a low of -$0.0 in Q2 2024.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$0.0, with a median of -$0.0 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 426.77% in 2024, then decreased 10.69% in 2025.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.0 in 2023, then skyrocketed by 426.77% to $0.0 in 2024, then plummeted by 112.06% to -$0.0 in 2025.
  • Per Business Quant, the three most recent readings for GWLL's EPS (Weighted Average and Diluted) are -$0.0 (Q3 2025), -$0.0 (Q2 2025), and -$0.0 (Q1 2025).